[In vitro antitumor immune response induced by fusion of dendritic cells and Ewing's sarcoma cells].
OBJECTIVE: Human Ewing sarcoma A673 cells and human peripheral blood-derived DCs were fused to induce an antitumor activity against human EW. METHODS: EW A673 cells and human peripheral blood-derived DCs were fused with polyethylene glycol (PEG). RESULTS: Mature DCs with highly expressed surface markers (CD80, CD86, CD83 and HLA-DR) were generated in vitro and flow cytometry. It showed that the highest fusion efficiency was 23.01%. T cell proliferation assay indicated that the novel dendritomas in fused DCs/A673 cells were the most potent in activation of autologous T cell proliferation. The IFN-gamma assay showed that The IFN-gamma secretion by CTLs activated by the novel dendritomas increased more than by other stimulators. CTL assay demonstrated that the novel dendritomas induced A673 cell-specific cytotoxic responses to lyse the A673 cells in the context of MHC class I. CONCLUSION: The data indicates that fusion of tumor cells with DCs is an attractive strategy to induce tumor rejection.